Atara Biotherapeutics Crescita futura

Future criteri di controllo 1/6

Si prevede che Atara Biotherapeutics aumenterà gli utili e i ricavi rispettivamente del 47.9% e 17.8% all'anno, mentre si prevede che l'EPS crescerà del 27.2% all'anno.

Informazioni chiave

47.9%

Tasso di crescita degli utili

27.2%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	41.8%
Tasso di crescita dei ricavi	17.8%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Good
Ultimo aggiornamento	21 Aug 2024

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Previsioni di crescita degli utili e dei ricavi

DB:AT20 - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	103	-67	-115	-60	4
12/31/2025	94	-98	-22	-39	6
12/31/2024	103	-91	-25	-6	6
6/30/2024	62	-181	-142	-142	N/A
3/31/2024	35	-233	-185	-184	N/A
12/31/2023	9	-276	-194	-193	N/A
9/30/2023	5	-290	-201	-199	N/A
6/30/2023	7	-305	-214	-213	N/A
3/31/2023	57	-215	-226	-224	N/A
12/31/2022	64	-228	-275	-270	N/A
9/30/2022	71	-247	-254	-248	N/A
6/30/2022	72	-248	-252	-242	N/A
3/31/2022	24	-350	-250	-239	N/A
12/31/2021	20	-340	-231	-221	N/A
9/30/2021	13	-328	-199	-190	N/A
6/30/2021	7	-318	-190	-184	N/A
3/31/2021	4	-311	-185	-179	N/A
12/31/2020	N/A	-307	-185	-181	N/A
9/30/2020	N/A	-304	-242	-235	N/A
6/30/2020	N/A	-301	-242	-235	N/A
3/31/2020	N/A	-298	-239	-232	N/A
12/31/2019	N/A	-291	-241	-236	N/A
9/30/2019	N/A	-292	-242	-234	N/A
6/30/2019	N/A	-279	-241	-230	N/A
3/31/2019	N/A	-256	-232	-215	N/A
12/31/2018	N/A	-231	-216	-180	N/A
9/30/2018	N/A	-186	-189	-147	N/A
6/30/2018	N/A	-159	-163	-119	N/A
3/31/2018	N/A	-135	N/A	-100	N/A
12/31/2017	N/A	-119	N/A	-88	N/A
9/30/2017	N/A	-102	N/A	-84	N/A
6/30/2017	N/A	-97	N/A	-79	N/A
3/31/2017	N/A	-88	N/A	-70	N/A
12/31/2016	N/A	-79	N/A	-60	N/A
9/30/2016	N/A	-82	N/A	-50	N/A
6/30/2016	N/A	-69	N/A	-48	N/A
3/31/2016	N/A	-65	N/A	-43	N/A
12/31/2015	N/A	-57	N/A	-37	N/A
9/30/2015	N/A	-46	N/A	-31	N/A
6/30/2015	N/A	-41	N/A	-22	N/A
3/31/2015	N/A	-30	N/A	-20	N/A
12/31/2014	N/A	-28	N/A	-17	N/A
9/30/2014	N/A	-21	N/A	-14	N/A
6/30/2014	N/A	-18	N/A	-12	N/A
3/31/2014	N/A	-15	N/A	-8	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che AT20 rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che AT20 rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che AT20 rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di AT20 ( 17.8% all'anno) crescerà più rapidamente del mercato German ( 5.7% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di AT20 ( 17.8% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di AT20 è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2024/09/14 12:35
Prezzo dell'azione a fine giornata	2024/06/18 00:00
Guadagni	2024/06/30
Guadagni annuali	2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

^* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .

Fonti analitiche

Atara Biotherapeutics, Inc. è coperta da 14 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
John Newman	Canaccord Genuity
Yigal Nochomovitz	Citigroup Inc
Jonathan Miller	Evercore ISI

Atara Biotherapeutics Crescita futura

Future criteri di controllo 1/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

Atara Biotherapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Atara Biotherapeutics, Inc. Appoints Eric Hyllengren as Chief Operating Officer

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $36 million.

Atara Biotherapeutics, Inc. Announces CEO Changes, Effective September 9, 2024

Atara Biotherapeutics Announces U.S. Fda Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-Cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

New major risk - Financial position

Atara Biotherapeutics Submits Tabelecleucel (Tab-cel) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA

First quarter 2024 earnings released: US$0.23 loss per share (vs US$0.72 loss in 1Q 2023)

Atara Biotherapeutics, Inc., Annual General Meeting, Jun 10, 2024

Full year 2023 earnings released: US$2.61 loss per share (vs US$2.24 loss in FY 2022)

Atara Biotherapeutics, Inc. Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

Atara Biotherapeutics, Inc. and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel®? Data in The Lancet Oncology

Atara Biotherapeutics, Inc. has announced a Derivatives Offering in the amount of $15 million.

Atara Biotherapeutics, Inc. Announces Termination of Manher (Aj) Joshi as Executive Vice President, Chief Medical Officer, Effective as of February 2, 2024

Atara Biotherapeutics, Inc. Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

Independent Director recently bought €95k worth of stock

New minor risk - Market cap size

Atara Biotherapeutics, Inc. Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis

Atara Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Financial position

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2023 earnings released: US$0.66 loss per share (vs US$0.82 loss in 3Q 2022)

Atara Biotherapeutics, Inc. Announces Plans to Submit Tab-cel® BLA in Second Quarter 2024 Following FDA Agreement on Comparability

New major risk - Revenue and earnings growth

Atara Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Financial position

Atara Biotherapeutics, Inc. Announces Resignation of Beth Seidenberg from the Board of Directors

Insufficient new directors

President recently sold €56k worth of stock

Atara Biotherapeutics, Inc. Announces Executive Changes

Full year 2022 earnings released: US$2.24 loss per share (vs US$3.63 loss in FY 2021)

Pierre Fabre and Atara Biotherapeutics Announce the Transfer of the European Commission Marketing Authorization for EBVALLO(TM)

Atara Biotherapeutics, Inc. to Report Q4, 2022 Results on Feb 08, 2023

Atara Biotherapeutics Announces Changes to Its Board of Directors

Atara Biotherapeutics, Inc. Appoints Carol Gallagher as Chair of the Board of Directors

Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (Allele) of Tab-Cel(R) At the 64Th American Society of Hematology (Ash) Annual Meeting

Third quarter 2022 earnings released: US$0.82 loss per share (vs US$0.91 loss in 3Q 2021)

Atara Biotherapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Atara Biotherapeutics, Inc. Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022

CHMP Recommends Approval of Atara Biotherapeutics, Inc. Ebvallo (Tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics, Inc. to Terminate Kristin Yarema as Senior Vice President and Chief Commercial Officer, Effective as of November 15, 2022

Atara Biotherapeutics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Atara Biotherapeutics, Inc. Announces Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MS

Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expanded Access Program (EAP) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and Update on Tab-cel EMA Regulatory Progress

Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer

Atara and MSK Expects to Provide A Phase 1 Data Update for Ata2271 in Second Half 2022

Atara Biotherapeutics, Inc. Names Charlene Banard as Chief Technical Officer

Atara Biotherapeutics, Inc. Provides Update on ATA2271 Autologous CAR T Trial

Atara Biotherapeutics, Inc. to Report Fiscal Year 2021 Results on Feb 28, 2022

FUJIFILM Diosynth Biotechnologies California, Inc. entered into an asset purchase agreement to acquire T-Cell Operations and Manufacturing Facility in Thousand Oaks, California from Atara Biotherapeutics, Inc. (NasdaqGS:ATRA) for $100 million.

Atara Biotherapeutics, Inc. Lauds the Second High Impact Study This Month Solidifying EBV as the Primary Driver of the Development of MS

Atara Biotherapeutics, Inc. to Complete the Biologics License Application for Patients with EBV+ PTLD in Second Quarter of 2022

Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting

Atara Biotherapeutics, Inc. Announces New Preclinical and Preliminary Clinical Results for ATA2271 at ESMO Immuno-Oncology Congress 2021

Atara Biotherapeutics, Inc. Announces That the Marketing Authorization Application for Tabelecleucel (Tab-Cel®) Has Been Fully Validated by the European Medicines Agency

European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of Tab-Cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (Ptld)

High number of new directors

Atara Biotherapeutics Announces Operational Progress on Tabelecleucel (Tab-Cel®) for Post-Transplant Lymphoproliferative Disease (PTLD)

SVP & Chief Commercial Officer recently bought €413k worth of stock

Atara Biotherapeutics Presents Positive Tab-Cel Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect

Atara Biotherapeutics Presents New Long-Term Overall Survival Data from A Combined Analysis of Phase 2 Tab-Cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease At the Ebmt 2021 Annual Meeting

Atara Biotherapeutics, Inc. Reports Operational Progress

New 90-day low: €13.90

Atara Biotherapeutics, Inc. to Report Q4, 2020 Results on Mar 01, 2021

Atara Biotherapeutics Presents Key Data for Advancing the Development of Tab-cel® and ATA188 at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience

Atara Biotherapeutics Provides Regulatory Update for Tab-Cel(R) for Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $174.999792 million.

Atara Biotherapeutics Presents First Preclinical Evaluation of ATA3219 at the 62 American Society of Hematology Annual Meeting

Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors

New 90-day high: €22.04

New 90-day high: €15.35

Atara Biotherapeutics, Inc. Presents New Preclinical Data on ATA3271 at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020)

Atara Biotherapeutics, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Atara Biotherapeutics, Inc. to Report Q2, 2020 Results on Aug 05, 2020

Previsioni di crescita degli utili e dei ricavi